Does a BMI of 26 meet the threshold for Wegovy?

What the licensed BMI thresholds actually mean for a BMI of 26

The Wegovy SmPC, which sets the boundaries for lawful prescribing in the UK, specifies two routes to eligibility. The first is a BMI of 30 or above with no additional conditions required. The second is a BMI of 27 or above where the patient has at least one weight-related comorbidity, for example, hypertension, dyslipidaemia, obstructive sleep apnoea, or type 2 diabetes. A BMI of 26 sits below both of those thresholds in the standard framing, which is the direct answer most people looking at this question need.

There is one important adjustment. UK clinical guidance, including the criteria discussed in NICE's appraisal of semaglutide for weight management (TA875), recognises that people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds carry comparable cardiometabolic risk at lower BMI values. The standard NHS England application reduces each threshold by 2.5 kg/m² for those groups. That brings the condition-linked threshold from 27 down to 24.5, meaning a BMI of 26 with a qualifying condition could fall within scope for some patients. A prescriber looks at this on an individual basis; a number alone is never the whole answer.

If you want to understand how the BMI thresholds for Wegovy map onto the broader eligibility picture, the full guide to BMI requirements for Wegovy sets out each scenario clearly. You can also use the NHS BMI calculator to confirm your figure before a consultation.

What the STEP 1 trial tells us, and what it doesn't

The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults with a BMI of 30 or above, or 27 and above with a weight-related condition. Average body-weight reduction over 68 weeks was around 15% at the 2.4mg maintenance dose. That evidence base is robust, but it was built on participants who met those entry criteria, the trial does not extend its findings to people with a BMI of 26 who had no qualifying condition, and the licence reflects that boundary directly.

This matters for a practical reason: the licensed eligibility criteria are not arbitrary gatekeeping. They reflect the population in whom safety and efficacy were studied. Prescribing outside that population would require clinical justification, and any reputable prescriber will work within the approved framework. If your BMI is close to 27 and you do have a health condition your GP has noted, that conversation is worth having in a proper clinical review rather than trying to navigate it alone.

People whose BMI sits at 25 face a similar question, there is a separate look at Wegovy eligibility at BMI 25 if that's closer to your figure. At the other end, eligibility from BMI 30 upwards is more straightforward and is covered in its own guide.

NHS access versus a private prescription at BMI 26

If you're thinking about NHS access specifically, the picture is stricter still. NICE TA875 recommends Wegovy only within a specialist weight management service, with multidisciplinary support, and for a maximum of two years. NHS England's current phased rollout prioritises people with higher BMI values and multiple comorbidities. At a BMI of 26, NHS access is extremely unlikely under current criteria regardless of background.

A private prescription from a regulated pharmacy follows the licensed SmPC thresholds rather than NICE's NHS-specific recommendation, which is why the eligibility conversation for a private route centres on the 27-with-a-condition threshold rather than the more restrictive specialist-service criteria. It's worth being honest with yourself about this: if you're researching Wegovy at a BMI of 26 because you feel frustrated that your concern isn't being taken seriously elsewhere, that's a real and fair feeling, but a clinician still needs to be the one who decides whether treatment is appropriate for you.

For a broader look at what semaglutide eligibility involves at this BMI range, the guide to semaglutide at BMI 26 covers the licensed framework in more detail. You can also explore how Wegovy works and what treatment involves before deciding whether to take the next step.

Starting a consultation if you're close to the threshold

A consultation with a GPhC-registered prescriber is the only way to get a definitive answer about your specific situation. At nume, a qualified Independent Prescriber (not an automated system) personally reviews every application the same day. That review takes into account your BMI, your health history, any existing conditions, your background, and any medicines you already take.

If you are approved, treatment is dispatched the same day for orders placed before 12pm on a working day, arriving via tracked DPD delivery the next working day in plain packaging. The consultation, prescription, delivery and ongoing clinical aftercare are all included in one price, with no subscription tied to it. You can see what treatment involves on the weight-loss treatments page, or check the Wegovy cost guide to understand what private treatment pricing looks like. If you have questions before starting, our FAQs cover the most common ones.

If your BMI sits right at or just above 27 and you have a qualifying condition, a free consultation is the practical next step. Check your eligibility today.